Cystic Fibrosis Clinical Trial
Official title:
The Effect of Ghrelin on Appetite and Immune Function in Patients With Cystic Fibrosis
Background to ghrelin Ghrelin is a naturally occurring hormone found in the blood which
stimulates appetite. In healthy individuals, levels of ghrelin are high before a meal and
falls afterwards. Previous studies have shown that giving ghrelin (by injection) to thin
patients with renal failure and cancer increases their food intake. Furthermore, addition of
ghrelin may also reduce inflammation within the body. Cystic Fibrosis (CF) is a genetic
disease which frequently results in recurrent lung infections (leading to progressive
inflammatory lung damage) and low body weight. Low body weight in CF is associated with
increased lung infections, rapidly worsening lung function and a shortened life expectancy.
The researchers postulate that administration of extra ghrelin to CF patients with low body
weight may increase food intake and reduce lung inflammation. If successful, this study
might identify ghrelin as a potential therapy for CF patients to improve nutrition, decrease
lung inflammation and thereby improve survival.
The purpose of this study is to investigate the role of a naturally occuring hormone called
ghrelin on appetite, energy expenditure and immune function in patients with cystic
fibrosis.
Theoretical framework:
Despite advances in the molecular understanding of the disease, life−expectancy in Cystic
Fibrosis (CF) remains severely limited. Reduced body−weight is associated with increased
inflammatory lung damage and is a major predictor of mortality in CF patients. Malnutrition
is highly prevalent in the CF population and results from both poor food intake and
excessive energy expenditure. A therapy which improves nutrition may therefore have a
significant effect on the prognosis of this disease. Ghrelin is the only physiological
circulating factor that is known to increase food intake. Administration of acylated ghrelin
to humans increases both hunger and food intake and has been found to increase appetite in
chronic disease states associated with anorexia and weight loss (such as cancer and chronic
renal disease). From multiple animal and in vitro human studies, ghrelin also appears to
have anti−inflammatory properties which would potentially benefit CF patients in whom a
chronic inflammatory state promotes lung destruction, malnutrition and increases mortality.
Ghrelin replacement may therefore improve nutrition and decrease the inflammatory burden in
CF patients, leading to an improvement in life−expectancy. If ghrelin is identified as
having an important pathophysiological role in CF it may lead to a future study of its
efficacy as a therapeutic agent.
Design Methodology: The study has three sections:
1. a cross sectional study of the levels of blood metabolic signals in participants with
cystic fibrosis and healthy controls.
2. a laboratory study of the effect of ghrelin on immune cells extracted from the blood of
participants with cystic fibrosis and healthy controls
3. a cross−over interventional study of repeated ghrelin administration in malnourished
cystic fibrosis patients
;
Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
| Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
| Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
| Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
| Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
| Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
| Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
| Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
| Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
| Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
| Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
| Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
| Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
| Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
| Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
| Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
| Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
| Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
| Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
| Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |